• Consensus Rating: Moderate Buy
  • Consensus Price Target: $29.00
  • Forecasted Upside: 49.10%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$19.45
▲ +0.25 (1.30%)

This chart shows the closing price for VCYT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Veracyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VCYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VCYT

Analyst Price Target is $29.00
▲ +49.10% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Veracyte in the last 3 months. The average price target is $29.00, with a high forecast of $34.00 and a low forecast of $21.00. The average price target represents a 49.10% upside from the last price of $19.45.

This chart shows the closing price for VCYT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Veracyte. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$32.00 ➝ $28.00Low
2/26/2024Morgan StanleyLower TargetUnderweight ➝ Underweight$22.00 ➝ $21.00Low
2/23/2024William BlairReiterated RatingOutperformLow
2/23/2024Needham & Company LLCBoost TargetBuy ➝ Buy$30.00 ➝ $33.00Low
11/10/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$23.00 ➝ $22.00Low
11/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$35.00 ➝ $30.00Low
11/8/2023William BlairReiterated RatingOutperformLow
10/20/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$37.00 ➝ $32.00Low
10/10/2023StephensReiterated RatingOverweight ➝ Overweight$34.00Low
8/9/2023Needham & Company LLCBoost TargetBuy ➝ Buy$34.00 ➝ $35.00Low
8/9/2023Morgan StanleyBoost TargetUnderweight ➝ Underweight$22.00 ➝ $23.00Low
2/23/2023Needham & Company LLCBoost TargetBuy$33.00 ➝ $34.00Low
1/18/2023Raymond JamesDowngradeOutperform ➝ Market PerformLow
1/4/2023ScotiabankInitiated CoverageSector Outperform$33.00Low
11/4/2022Morgan StanleyLower TargetUnderweight$23.00 ➝ $22.00Low
11/4/2022Raymond JamesLower TargetOutperform$31.00 ➝ $27.00Low
11/3/2022SVB LeerinkBoost TargetOutperform$30.00 ➝ $35.00Low
11/3/2022Needham & Company LLCBoost TargetBuy$31.00 ➝ $33.00Low
11/2/2022William BlairReiterated RatingOutperformLow
8/4/2022Raymond JamesBoost TargetOutperform$30.00 ➝ $31.00N/A
8/3/2022Needham & Company LLCBoost TargetBuy$26.00 ➝ $31.00Low
5/4/2022Needham & Company LLCLower Target$31.00 ➝ $26.00High
3/15/2022Needham & Company LLCLower TargetBuy$35.00 ➝ $31.00High
3/2/2022StephensLower TargetOverweight$52.00 ➝ $44.00Medium
3/1/2022Lake Street CapitalLower Target$95.00 ➝ $50.00High
3/1/2022Needham & Company LLCLower Target$55.00 ➝ $35.00Low
3/1/2022Raymond JamesLower TargetOutperform$62.00 ➝ $34.00Medium
3/1/2022SVB LeerinkLower TargetOutperform$45.00 ➝ $40.00Medium
1/7/2022StephensInitiated CoverageOverweight$52.00High
11/18/2021The Goldman Sachs GroupInitiated CoverageBuy$59.00Low
11/10/2021William BlairReiterated RatingOutperformMedium
11/10/2021Raymond JamesBoost TargetOutperform$50.00 ➝ $62.00High
7/30/2021Morgan StanleyLower TargetUnderweight$45.00 ➝ $42.00Medium
7/30/2021Needham & Company LLCBoost TargetBuy$54.00 ➝ $55.00High
7/30/2021SVB LeerinkBoost TargetOutperform$55.00 ➝ $60.00High
7/14/2021SVB LeerinkLower TargetOutperform$65.00 ➝ $55.00High
6/28/2021Raymond JamesBoost TargetOutperform$45.00 ➝ $50.00Medium
6/25/2021Needham & Company LLCReiterated RatingBuyHigh
6/15/2021Raymond JamesInitiated CoverageOutperform$45.00Medium
5/27/2021William BlairReiterated RatingBuyMedium
5/18/2021Truist FinancialLower TargetBuy ➝ Buy$84.00 ➝ $55.00High
5/12/2021Morgan StanleyLower TargetUnderweight$65.00 ➝ $45.00Medium
5/11/2021SVB LeerinkLower TargetOutperform$75.00 ➝ $65.00High
5/11/2021Needham & Company LLCLower TargetIn-Line ➝ Buy$88.00 ➝ $54.00Low
4/27/2021SVB LeerinkLower TargetOutperform$85.00 ➝ $75.00High
4/14/2021Needham & Company LLCReiterated RatingBuy$88.00High
2/25/2021Morgan StanleyBoost TargetUnderweight$35.00 ➝ $65.00Medium
2/18/2021SVB LeerinkBoost TargetOutperform$83.00 ➝ $85.00High
2/8/2021SVB LeerinkBoost TargetOutperform$40.00 ➝ $83.00High
1/27/2021Truist FinancialInitiated CoverageBuy$61.00High
12/17/2020Lake Street CapitalBoost TargetBuy$40.00 ➝ $60.00High
12/17/2020BTIG ResearchBoost TargetBuy$42.00 ➝ $56.00High
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$48.00High
11/4/2020BTIG ResearchBoost TargetBuy$38.00 ➝ $42.00High
11/3/2020Needham & Company LLCBoost TargetBuy$37.00 ➝ $40.00High
11/3/2020SVB LeerinkBoost TargetOutperform$37.00 ➝ $40.00High
11/2/2020William BlairReiterated RatingOutperformHigh
10/2/2020Needham & Company LLCReiterated RatingBuy$37.00Medium
9/9/2020Morgan StanleyInitiated CoverageUnderweight$35.00Low
7/31/2020Lake Street CapitalBoost TargetBuy$35.00 ➝ $40.00High
7/31/2020Needham & Company LLCBoost TargetBuy$30.00 ➝ $37.00High
7/31/2020SVB LeerinkBoost TargetOutperform$32.00 ➝ $37.00High
5/7/2020SVB LeerinkBoost TargetOutperform$29.00 ➝ $32.00Low
5/7/2020Needham & Company LLCReiterated RatingBuy$30.00Low
2/26/2020Needham & Company LLCLower TargetBuy$34.00 ➝ $30.00High
12/4/2019Lake Street CapitalReiterated RatingBuy$35.00High
12/4/2019Needham & Company LLCReiterated RatingBuy$34.00High
11/18/2019Needham & Company LLCReiterated RatingBuy$34.00Medium
10/28/2019Needham & Company LLCReiterated RatingBuy$34.00High
7/31/2019Needham & Company LLCSet TargetBuy$34.00High
7/31/2019Lake Street CapitalInitiated CoverageBuy ➝ Buy$35.00High
7/2/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$33.00Medium
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/23/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/23/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
12/22/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 14 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 8 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Veracyte logo
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $19.45
Low: $19.02
High: $19.54

50 Day Range

MA: $22.15
Low: $18.86
High: $26.52

52 Week Range

Now: $19.45
Low: $18.61
High: $30.52

Volume

1,360,124 shs

Average Volume

571,994 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Veracyte?

The following sell-side analysts have issued stock ratings on Veracyte in the last twelve months: Morgan Stanley, Needham & Company LLC, Stephens, StockNews.com, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for VCYT.

What is the current price target for Veracyte?

4 Wall Street analysts have set twelve-month price targets for Veracyte in the last year. Their average twelve-month price target is $29.00, suggesting a possible upside of 49.1%. Stephens has the highest price target set, predicting VCYT will reach $34.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $21.00 for Veracyte in the next year.
View the latest price targets for VCYT.

What is the current consensus analyst rating for Veracyte?

Veracyte currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for VCYT.

What other companies compete with Veracyte?

How do I contact Veracyte's investor relations team?

Veracyte's physical mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 243-6300 and its investor relations email address is [email protected]. The official website for Veracyte is www.veracyte.com. Learn More about contacing Veracyte investor relations.